Effect of Myrtus Communis in Gastro esophageal reflux disease

Evaluation the effect of Myrtus Communis L. (Myrtle) fruit syrup, Traditional Iranian Medicine compound, on relapsing of Gastro esophageal reflux disease in patients 20 to 60 years old: a double blinded randomized controlled trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014102719705N1

Enrollment

Registered

2015-05-10

Start date

2015-01-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro esophageal reflux disease. Gastro-oesophageal reflux disease

Interventions

Intervention 1: Case group: Oral syrup of Myrtus Communis L. (Myrtle) fruit, 5 cc after each meal, Breakfast and Lunch and Dinner, and Omeprazole capsule 20mg with fasting, for 6 Weeks Myrtus Communis

Treatment - Drugs

Case group: Oral syrup of Myrtus Communis L. (Myrtle) fruit, 5 cc after each meal, Breakfast and Lunch and Dinner, and Omeprazole capsule 20mg with fasting, for 6 Weeks Myrtus Communis L. (Myrtle) fr

Control group: Placebo syrup of Myrtus Communis L. (Myrtle) fruit, 5 cc after each meal, Breakfast and Lunch and Dinner, and Omeprazole capsule 20mg with fasting, for 6 Weeks Intervention time is 6

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with 20-60 years old; having reflux symptoms more than once a week. Exclusion criteria: Liver failure; cancer; pregnant women; surgery on stomach or esophagus; significant weight loss in 3 last months; melena or hematemesis; IBD; using PPI in the past 1 month; frequent using of NSAIDs.; severe chest pain; BMI>40; unwillingness to cooperation in study; sever complication; sensitivity to Myrtus Communis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Relapsing of Gastro esophageal reflux. Timepoint: At first, end of the sixth week, end of the eighth week. Method of measurement: Gastro esophageal reflux standard questionnaire.	—

Secondary

Measure	Time frame
Heartburn. Timepoint: At first, end of the sixth week, end of the eighth week. Method of measurement: Gastro esophageal reflux standard questionnaire.;Acid regurgitation. Timepoint: At first, end of the sixth week, end of the eighth week. Method of measurement: Gastro esophageal reflux standard questionnaire.;Chestpain. Timepoint: At first, end of the sixth week, end of the eighth week. Method of measurement: Gastroesophageal reflux standard questionnaire.;Dysphagia. Timepoint: At first, end of the sixth week, end of the eighth week. Method of measurement: Gastroesophageal reflux standard questionnaire.	—

Measure

Time frame

Heartburn. Timepoint: At first, end of the sixth week, end of the eighth week. Method of measurement: Gastro esophageal reflux standard questionnaire.;Acid regurgitation. Timepoint: At first, end of the sixth week, end of the eighth week. Method of measurement: Gastro esophageal reflux standard questionnaire.;Chestpain. Timepoint: At first, end of the sixth week, end of the eighth week. Method of measurement: Gastroesophageal reflux standard questionnaire.;Dysphagia. Timepoint: At first, end of the sixth week, end of the eighth week. Method of measurement: Gastroesophageal reflux standard questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Salehi

Tehran University of Medical Sciences

m_salehi@razi.tums.ac.ir+98 21 3331 8165

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026